Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilars Payments In Medicare: CMS Signals Willingness To Change

Jul 17 2017

• By Cathy Kelly

Anti-recessionary injection (vaccination) by hundred dollar denomination close up on a black background

Related Content

US Biosimilars: 40% First-Cycle Approval Rate Leaves Room For Improvement

Jul 06 2017

Doc Groups Seek To Block CMS Biosimilars Policy Via Congress

Dec 09 2015

Samsung’s Renflexis: Second US Biosimilar To Janssen’s Remicade, With A Few Firsts

Apr 22 2017

CMS Sticks With Combining Biosimilars In Single Medicare Payment Code

Oct 30 2015

Related Companies

Novartis AG

Celltrion, Inc.

Merck & Co., Inc.

Johnson & Johnson

Apotex Inc.

Amgen, Inc.

AbbVie Inc.

Additional Topics

United States Biosimilars Reimbursement BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.